OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 110 participants.
Also called NCT04789239
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 110 participants
- Sponsor
- Registry
-
NCT04789239
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Sweden
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04789239. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
- Acronym
- OPRA-HF
- Condition
- Heart Failure
- Condition
- Hyperkalemia
- Intervention (Drug)
- Sodium zirconium cyclosilicate
- Intervention (Other)
- Placebo
- Lead sponsor
- Michael Fu
- Collaborator
- AstraZeneca
- Collaborator
- Göteborg University
Record details
- Record id
cardio:ct-nct04789239- Content hash
c3ea37fa9d82828ae3c155940a102d79b1b56f1f743ea912e92c7f1d3ef67cdf